Pharma Cost Pressures Will Erode Value But Foster Adaptation
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 15 Analysts
Published
10 Aug 25
Updated
20 Aug 25
AnalystLowTarget's Fair Value
US$300.00
0.7% overvalued intrinsic discount20 Aug
US$302.19
1Y
-11.7%7D
3.6%